Navigation Links
European Multidisciplinary Conference in Thoracic Oncology -- press program
Date:2/23/2011

The following studies will be presented in the Press Program of the second European Multidisciplinary Conference in Thoracic Oncology, a multipartner initiative for physicians of all medical disciplines dealing with lung cancer and other thoracic malignancies.

The full text of the embargoed press releases/abstracts can be requested to the EMCTO Press Office at media@esmo.org. When the embargo lifts, the texts will be available in the ESMO Online Newsroom.

  1. Quick, easy test identifies aggressive type of lung cancer in never-smokers (embargo: 25 February 2011, 8:00 CET)
    Inexpensive and rapid test can effectively identify sub-group of never-smoking lung cancer patients whose tumors express molecule associated with increased risk of disease progression or recurrence.
    Author: Ping Yang, US

  2. Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer (embargo: 25 February 2011, 8:00 CET)
    Researchers identified a gene whose expression level strongly predicts how well and how long certain lung cancer patients will respond to treatment with erlotinib.
    Author: Rafael Rosell, Spain

  3. Bone drug zoledronic acid may help prevent spread of early lung cancer (embargo: 25 February 2011, 8:00 CET)
    Drug currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier state of treatment to prevent cancer from spreading.
    Author: Michela Quirino, italy

  4. Radio-guided surgery, a safe and simple way to remove potentially cancerous nodules in the lung (embargo: 26 February 2011, 8:00 CET)
    Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques.
    Author: Luca Bertolaccini, Italy

  5. Phase III trial: erlotinib as effective as chemo, with fewer side-effects, in patients whose disease progressed after first-line treatment (embargo: 26 February 2011, 8:00 CET)
    Targeted cancer drug erlotinib has comparable efficacy to chemotherapy and is better tolerated in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy.
    Author: Tudor Ciuleanu, Romania


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. IOF calls on European citizens to stand tall and speak out for their bones
2. IronKey Opens New European Office
3. European researchers harness unique properties of boron to develop new drugs and diagnostics
4. Vidaza receives positve opinion from European CHMP
5. The MDS foundation supports vidazas recommendation for European approval
6. European biodiversity and ecosystem scientists merge and gear up for long-term research
7. Overfishing threatens European bluefin tuna
8. European ancestry increases breast cancer risk among Latinas
9. IRB Barcelona to coordinate two European projects on biomedicine
10. Key to future medical breakthroughs is systems biology, say leading European scientists
11. Global warming linked to European viral epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:5/6/2016)... ... 06, 2016 , ... Crucial Life Sciences Data Solutions, Inc. ... improves performance of the platform. In particular, Version 4.1 boosts performance for complex ... to be collected on a per patient basis. Clinical Studio has employed a ...
(Date:5/5/2016)... ... May 05, 2016 , ... American Process, Inc. (API) announced ... Patent Nos. 9,322,133 and 9,322,134, to API and its affiliated companies for BioPlus® ... hydrophobic nanocellulose compositions. In addition to these patents and U.S. Patent No. ...
(Date:5/4/2016)... ... 05, 2016 , ... CereScan, the nation’s leader in providing ... National Stroke Awareness Month in May. An infographic created by CereScan will ... CereScan will donate $1 up to a maximum of $3,000 through users who ...
(Date:5/4/2016)... 4, 2016  Bayer today announced that a ... ® (regorafenib) tablets for the treatment of ... its primary endpoint of a statistically significant improvement ... the efficacy and safety of regorafenib in patients ... with sorafenib. The safety and tolerability were generally ...
Breaking Biology Technology: